Simultaneous determination of a new anticancer agent (NB-506) and its active metabolite in human plasma and urine by high-performance liquid chromatography with ultraviolet detection.
A high-performance liquid chromatographic method with ultraviolet detection has been developed to quantify NB-506 and its active metabolite in human plasma and urine. This method is based on solid-phase extraction, thereby allowing the simultaneous measurement of the drug and metabolite with the limit of quantification of 0.01 microgram/ml in plasma and 0.1 microgram/ml in urine. Standard curves for the compounds were linear in the concentration ranges investigated. The range for the drug in plasma was 0.01-2.5 micrograms/ml, and for the metabolite 0.01-1 microgram/ml. In urine, the range for both compounds was 0.1-10 micrograms/ml. The method was validated and applied to the assay of plasma and urinary samples from phase I studies.
Takenaga
N
N
Development Research Laboratories, Banyu Pharmaceutical Co., Ltd., Saitama, Japan.
Ishii
Y
Y
Monden
S
S
Sasaki
Y
Y
Hata
S
S
D000704:Analysis of Variance; D000970:Antineoplastic Agents / Q000032:analysis* / Q000097:blood / Q000378:metabolism / Q000652:urine; D002227:Carbazoles / Q000032:analysis* / Q000097:blood / Q000378:metabolism / Q000652:urine; D002851:Chromatography, High Pressure Liquid; D005960:Glucosides / Q000032:analysis* / Q000097:blood / Q000378:metabolism / Q000652:urine; D006801:Humans; D006863:Hydrogen-Ion Concentration; D012015:Reference Standards; D015203:Reproducibility of Results; D013056:Spectrophotometry, Ultraviolet
D000970:Antineoplastic Agents; D002227:Carbazoles; D005960:Glucosides; C092476:NB 506